SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

SAB Biotherapeutics (Nasdaq: SABS) announced that CEO Samuel J. Reich will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026 at 7:30 a.m. PT / 10:30 a.m. ET in San Francisco.

A live webcast will be available in the Investors section of the company website at www.sab.bio, and an archived replay will be posted for approximately 30 days after the presentation.

News Market Reaction – SABSW

+22.58%

+22.58% Session close to close

In the Jan 6 session, SABSW gained 22.58%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company’s CEO Samuel J. Reich will present at the 44^th Annual J.P. Morgan Healthcare Conference on Thursday, January 15 at 7:30 a.m. PT/10:30 a.m. ET in San Francisco, CA.

A live webcast of the presentation will be available in the “Investors” section of the SAB BIO website at www.sab.bio. An archived replay will be available on the Company’s website for approximately 30 days following the presentation.

About SAB BIO
SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc-Bovine™, to produce hIgG. SAB BIO’s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. For more information, visit www.sab.bio.

CONTACTS

Investor Relations:
Cristi Barnett
ir@sab.bio

Media:
Sheila Carlson
media@sab.bio

FAQ

When will SAB Biotherapeutics (SABS) present at the J.P. Morgan Healthcare Conference?

SAB Biotherapeutics will present on January 15, 2026 at 7:30 a.m. PT / 10:30 a.m. ET.

Who is presenting for SAB Biotherapeutics (SABS) at the January 2026 JPM conference?

The presentation will be delivered by CEO Samuel J. Reich.

How can investors watch the SAB Biotherapeutics (SABS) JPM presentation live?

A live webcast will be available in the Investors section of www.sab.bio.

Will SAB Biotherapeutics (SABS) provide a replay of the JPM presentation?

Yes. An archived replay will be available on the company website for approximately 30 days after the presentation.

What topics will SAB Biotherapeutics (SABS) likely cover in the JPM presentation?

The company is clinical-stage and develops hATG for type 1 diabetes and other autoimmune diseases, which are expected topics.

Where on the SAB Biotherapeutics (SABS) site is the JPM webcast posted?

The webcast will be posted in the Investors section of www.sab.bio.